Real-world study of xeligekimab in adults with moderate to severe plaque psoriasis
Observes how xeligekimab works and is tolerated in adults with plaque psoriasis.
Plain-language title generated from the registry record
Registry title: Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
Key facts
- Where
- Hunan, ChinaSee the site
Where in China
- Xiangya Hospital of Central South UniversityHunan, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chongqing Genrix Biopharmaceutical Co., Ltd
- Trial code
- NCT06802848
- Record updated
- 31 January 2025
- Original description
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy. Despite the promising efficacy and safety shown in the phase III clinical trial, real-world data is needed to further support clinical decisions for this patient group. This study aims to evaluate the effectiveness and safety of xeligekimab in real-world clinical settings for adults with moderate to severe plaque psoriasis.Read full original descriptionShow less
Effectiveness and Safety of Xeligekimab in Adult Patients With Moderate to Severe Plaque Psoriasis: A Multicenter, Prospective, Real-World Study
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy. Despite the promising efficacy and safety shown in the phase III clinical trial, real-world data is needed to further support clinical decisions for this patient group. This study aims to evaluate the effectiveness and safety of xeligekimab in real-world clinical settings for adults with moderate to severe plaque psoriasis.
Inclusion: Patients who meet all the following criteria will be included in this study:; Patients 18 years of age or older; Patients with a confirmed clinical diagnosis of moderate to severe plaque psoriasis at the time of screening; Patients who are deemed suitable for xeligekimab therapy by a clinician and are anticipated to receive xeligekimab treatment for the first time; Patients who are willing to sign the informed consent form.
Exclusion: Patients with hypersensitivity to the active ingredient or any excipient in xeligekimab injection solution; Patients under other conditions or circumstances that investigators do not consider appropriate to include; Patients with drug-induced psoriasis (such as new-onset or exacerbated psoriasis caused by β-blockers, calcium channel blockers, or lithium); Patients who meet any of the following exclusion criteria will be excluded from this study:; Patients with other contraindications specified in the prescribing information; Patients concurrently participating in other clinical studies.